Lisa K Stamp

Summary

Publications

  1. ncbi request reprint Expression of methotrexate transporters and metabolizing enzymes in rheumatoid synovial tissue
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    J Rheumatol 40:1519-22. 2013
  2. doi request reprint Hyperuricaemia and gout in New Zealand rural and urban Māori and non-Māori communities
    L K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    Intern Med J 43:678-84. 2013
  3. doi request reprint Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial
    Lisa K Stamp
    University of Otago, Christchurch, Christchurch, New Zealand
    Arthritis Rheum 65:1636-42. 2013
  4. doi request reprint A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets
    Amanda J Phipps-Green
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Hum Mol Genet 19:4813-9. 2010
  5. pmc Only one independent genetic association with rheumatoid arthritis within the KIAA1109-TENR-IL2-IL21 locus in Caucasian sample sets: confirmation of association of rs6822844 with rheumatoid arthritis at a genome-wide level of significance
    Jade E Hollis-Moffatt
    Department of Biochemistry, 710 Cumberland Street, University of Otago, Dunedin 9054, New Zealand
    Arthritis Res Ther 12:R116. 2010
  6. doi request reprint Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy
    Lisa K Stamp
    University of Otago, Christchurch, New Zealand
    Arthritis Rheum 62:359-68. 2010
  7. doi request reprint Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Māori, Pacific Island, and Caucasian case-control sample sets
    Jade E Hollis-Moffatt
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Arthritis Rheum 60:3485-92. 2009
  8. doi request reprint Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment
    Lisa K Stamp
    University of Otago, Christchurch, New Zealand
    Arthritis Rheum 63:412-21. 2011
  9. doi request reprint Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch 8140, New Zealand
    Rheumatology (Oxford) 51:1670-6. 2012
  10. doi request reprint Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    Pharmacogenet Genomics 20:367-76. 2010

Collaborators

Detail Information

Publications39

  1. ncbi request reprint Expression of methotrexate transporters and metabolizing enzymes in rheumatoid synovial tissue
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    J Rheumatol 40:1519-22. 2013
    ....
  2. doi request reprint Hyperuricaemia and gout in New Zealand rural and urban Māori and non-Māori communities
    L K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    Intern Med J 43:678-84. 2013
    ..There are few current data on the prevalence of hyperuricaemia and gout in New Zealand, particularly among the indigenous Māori population...
  3. doi request reprint Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial
    Lisa K Stamp
    University of Otago, Christchurch, Christchurch, New Zealand
    Arthritis Rheum 65:1636-42. 2013
    ..Studies in human volunteers have shown that vitamin C reduces serum urate (SU) levels. The aim of this study was to determine the effects of vitamin C on SU levels in patients with gout...
  4. doi request reprint A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets
    Amanda J Phipps-Green
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Hum Mol Genet 19:4813-9. 2010
    ....
  5. pmc Only one independent genetic association with rheumatoid arthritis within the KIAA1109-TENR-IL2-IL21 locus in Caucasian sample sets: confirmation of association of rs6822844 with rheumatoid arthritis at a genome-wide level of significance
    Jade E Hollis-Moffatt
    Department of Biochemistry, 710 Cumberland Street, University of Otago, Dunedin 9054, New Zealand
    Arthritis Res Ther 12:R116. 2010
    ..Here we aimed to: one, confirm at a genome-wide level of significance association of rs6822844 with RA and, two, evaluate whether or not there were effects independent of rs6822844 on RA at the KIAA1109-TENR-IL2-IL21 locus...
  6. doi request reprint Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy
    Lisa K Stamp
    University of Otago, Christchurch, New Zealand
    Arthritis Rheum 62:359-68. 2010
    ....
  7. doi request reprint Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Māori, Pacific Island, and Caucasian case-control sample sets
    Jade E Hollis-Moffatt
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Arthritis Rheum 60:3485-92. 2009
    ....
  8. doi request reprint Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment
    Lisa K Stamp
    University of Otago, Christchurch, New Zealand
    Arthritis Rheum 63:412-21. 2011
    ..To determine the efficacy and safety of increasing the allopurinol dose above the proposed creatinine clearance-based dose in patients with gout...
  9. doi request reprint Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch 8140, New Zealand
    Rheumatology (Oxford) 51:1670-6. 2012
    ..To determine the effects of furosemide on serum urate (SU), plasma oxypurinol and urinary urate...
  10. doi request reprint Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    Pharmacogenet Genomics 20:367-76. 2010
    ..To determine whether genetic polymorphisms within the folate pathway are associated with red blood cell (RBC) methotrexate (MTX) polyglutamate concentrations, RBC folate concentrations and MTX efficacy/toxicity...
  11. doi request reprint The population pharmacokinetics of allopurinol and oxypurinol in patients with gout
    Daniel F B Wright
    School of Pharmacy, University of Otago, PO Box 56, Dunedin, New Zealand
    Eur J Clin Pharmacol 69:1411-21. 2013
    ..The aims of this study were to develop a population pharmacokinetic model for allopurinol and oxypurinol and to explore the influence of patient characteristics on allopurinol and oxypurinol pharmacokinetics...
  12. pmc The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity
    Jade E Hollis-Moffatt
    Department of Biochemistry, University of Otago, 710 Cumberland Street, Dunedin 9012, New Zealand
    Arthritis Res Ther 13:R85. 2011
    ..There is no evidence for an association with gout in Caucasian populations. In the present study, we tested rs3733591 for association with gout in New Zealand (NZ) Māori, Pacific Island and Caucasian samples...
  13. pmc Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, 2 Riccarton Ave, Christchurch 8014, New Zealand
    Arthritis Res Ther 14:R138. 2012
    ..Furthermore, we investigated whether polymorphisms within ADORA3 were associated with response and/or adverse effects associated with MTX...
  14. doi request reprint Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    J Rheumatol 38:2540-7. 2011
    ..To determine the effects of changing from oral to subcutaneous (SC) methotrexate (MTX) in patients with rheumatoid arthritis (RA) on red blood cell MTX polyglutamate (RBC MTXGlu(n)) concentrations, disease activity, and adverse effects...
  15. doi request reprint Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis
    Judith M Dalrymple
    University of Otago, Christchurch, New Zealand
    Arthritis Rheum 58:3299-308. 2008
    ....
  16. doi request reprint Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment
    Lisa K Stamp
    Department of Mediicne, University of Otago, Christchurch, New Zealand
    Arthritis Rheum 60:2248-56. 2009
    ..This study was undertaken to determine nongenetic factors that influence red blood cell (RBC) MTXGlun concentrations in patients receiving long-term stable low-dose oral MTX...
  17. doi request reprint Monocyte derived interleukin (IL)-23 is an important determinant of synovial IL-17A expression in rheumatoid arthritis
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand
    J Rheumatol 36:2403-8. 2009
    ..To demonstrate gene expression of interleukin (IL)-17A, IL-23, and IL-12 and to determine the proximity of IL-17A and IL-23 producing cells in rheumatoid synovial tissue...
  18. doi request reprint A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells
    Julia Korell
    School of Pharmacy, University of Otago, PO Box 56, 9054 Dunedin, New Zealand
    Clin Pharmacokinet 52:475-85. 2013
    ....
  19. doi request reprint Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol
    Lisa K Stamp
    University of Otago, Christchurch, New Zealand
    Arthritis Rheum 64:2529-36. 2012
    ..However, the relationship between the allopurinol starting dose and AHS is unknown. This study was undertaken to determine the relationship between allopurinol dosing and AHS...
  20. doi request reprint Comparison of the 2010 American College of Rheumatology/European League Against Rheumatism and the 1987 American Rheumatism Association classification criteria for rheumatoid arthritis in an early arthritis cohort in New Zealand
    Rafi Raja
    Department of Rheumatology, Immunology and Allergy, Christchurch Hospital, and the Department of Medicine, University of Otago, Christchurch, New Zealand
    J Rheumatol 39:2098-103. 2012
    ....
  21. pmc The renal urate transporter SLC17A1 locus: confirmation of association with gout
    Jade E Hollis-Moffatt
    Department of Biochemistry, University of Otago, 710 Cumberland Street, Dunedin 9054, New Zealand
    Arthritis Res Ther 14:R92. 2012
    ..However, evidence for association with gout is equivocal. We investigated the association of the SLC17A1 locus with gout in New Zealand sample sets...
  22. pmc Association of variation in Fcgamma receptor 3B gene copy number with rheumatoid arthritis in Caucasian samples
    Cushla McKinney
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Ann Rheum Dis 69:1711-6. 2010
    ....
  23. doi request reprint Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials
    William J Taylor
    Department of Medicine, University of Otago, Wellington, New Zealand
    J Rheumatol 38:1467-70. 2011
    ..To review a novel approach for constructing composite response criteria for use in chronic gout clinical trials that implements a method of multicriteria decision-making...
  24. pmc Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    J Rheumatol 38:1462-6. 2011
    ..To summarize evidence for and endorsement of serum urate (SU) as having fulfilled the OMERACT filter as a soluble biomarker in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10)...
  25. doi request reprint Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases
    Lisa K Stamp
    Department of Biochemistry, University of Otago, Dunedin 9054, New Zealand
    Pharmacogenomics 12:1449-63. 2011
    ..Prospective studies, standardizing the definitions of response and toxicity, and application of genome-wide approaches may advance the search for genetic predictors of MTX response...
  26. doi request reprint Gout and its comorbidities: implications for therapy
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, PO Box 4345, Christchurch 8140, New Zealand
    Rheumatology (Oxford) 52:34-44. 2013
    ..This review will consider the relationship between comorbidities and gout with a particular focus on the treatment of gout and the potential interactions between drugs used for gout and those for comorbid conditions...
  27. doi request reprint The Christchurch earthquake--providing a rheumatology service during a natural disaster
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, Christchurch 8104, New Zealand
    Clin Rheumatol 31:723-5. 2012
    ....
  28. doi request reprint Different T cell subsets in the nodule and synovial membrane: absence of interleukin-17A in rheumatoid nodules
    Lisa K Stamp
    University of Otago, Christchurch, New Zealand
    Arthritis Rheum 58:1601-8. 2008
    ..To determine gene expression of the interleukin-17 (IL-17) family members (IL-17A-F) in rheumatoid subcutaneous nodules, and to assess the cytokines involved in regulating IL-17A expression...
  29. doi request reprint A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria
    Rebecca L Prowse
    University of Otago, Dunedin, New Zealand
    J Rheumatol 40:498-505. 2013
    ..To identify a comprehensive list of features that might discriminate between gout and other rheumatic musculoskeletal conditions, to be used subsequently for a case-control study to develop and test new classification criteria for gout...
  30. ncbi request reprint Antineutrophil cytoplasmic antibody measurement: advantages and disadvantages of a capture PR3 ELISA and a direct PR3 ELISA
    John L O'Donnell
    Department of Rheumatology, Immunology and Allergy, Canterbury Health Laboratories, Canterbury District Health Board, Christchurch, New Zealand
    Pathology 39:258-63. 2007
    ..To compare the performance of a capture proteinase 3 enzyme linked immunosorbent assay (PR3 ELISA) with a direct PR3 ELISA in the measurement of PR3 antineutrophil cytoplasmic antibodies (ANCA)...
  31. doi request reprint Cardiovascular morbidity in rheumatoid arthritis patients in North Canterbury, New Zealand 1999-2008
    Emon A R Khan
    Department of Rheumatology, Immunology and Allergy, Canterbury District Health Board, Christchurch, New Zealand
    Int J Rheum Dis 16:19-23. 2013
    ..Cardiovascular disease is a substantial contributor to increased morbidity and mortality in rheumatoid arthritis (RA). The aim of this audit was to determine the rate of cardiovascular events in a cohort of newly diagnosed RA patients...
  32. doi request reprint Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    Semin Arthritis Rheum 40:483-500. 2011
    ..To determine whether serum urate (SU) fulfills the Outcome measures in Rheumatology (OMERACT) soluble biomarker criteria...
  33. doi request reprint Gout and organ transplantation
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, P O Box 4345, Christchurch, 8140, New Zealand
    Curr Rheumatol Rep 14:165-72. 2012
    ..Other options include febuxostat and benzbromarone. The role of newer agents such as interleukin-1 inhibitors and uricases remains to be determined. General measures should include minimizing diuretic use...
  34. doi request reprint The challenges of gout management in the elderly
    Lisa K Stamp
    University of Otago, Christchurch, New Zealand
    Drugs Aging 28:591-603. 2011
    ..Careful consideration of the patient's concomitant medications is required as many drugs increase serum urate. Successful urate lowering will ultimately reduce gout flares and thereby improve patient quality of life...
  35. ncbi request reprint Leflunomide-associated infections in rheumatoid arthritis
    Katey A Jenks
    Department of Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
    J Rheumatol 34:2201-3. 2007
    ..To determine the prevalence of severe infections in patients with rheumatoid arthritis (RA) prescribed leflunomide in North Canterbury, New Zealand...
  36. ncbi request reprint Identification of a novel thiopurine S-methyltransferase allele (TPMT*37)
    Rebecca L Roberts
    aDepartment of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin bDepartment of Medicine, University of Otago Christchurch, Christchurch, New Zealand
    Pharmacogenet Genomics 24:320-3. 2014
    ..9 U/ml (reference range: 9.3-17.6 U/ml). TPMT*37 introduces a premature stop codon at position 216, resulting in loss of the last 29 amino acid residues from the C terminal of the TPMT protein. ..
  37. ncbi request reprint HLA-B27 associated spondyloarthropathy, vasculitis, and amyloid enteropathy: response to infliximab
    Lisa K Stamp
    Department of Medicine and Health Sciences, Christchurch School of Medicine, Otago University, Christchurch, New Zealand
    J Rheumatol 32:382-5. 2005
    ..Treatment with infliximab resulted in resolution of joint symptoms and rapid improvement in laboratory markers of inflammation. Diarrhea settled more gradually, such that her bowel habit had normalized 16 months after therapy commenced...
  38. ncbi request reprint Comparison of two plasma urate assays in patients receiving vitamin C supplementation
    Christiaan W Sies
    1Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch 2Department of Medicine, University of Otago, Christchurch 3Department of Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
    Pathology 46:333-5. 2014
    ..The assay which does not include ascorbate oxidase results in consistently lower PU concentrations compared to the assay which includes ascorbate oxidase...
  39. pmc The ITGAV rs3738919 variant and susceptibility to rheumatoid arthritis in four Caucasian sample sets
    Jade E Hollis-Moffatt
    Department of Biochemistry, University of Otago, 710 Cumberland Street, Dunedin 9054, New Zealand
    Arthritis Res Ther 11:R152. 2009
    ..We therefore tested this association in an independent study using New Zealand (NZ) and Oxford (UK) RA case control samples...